Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.22.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents [note 7] $ 43,022 $ 35,853
Grant receivable [note 4] 153  
Prepaid expenses and other assets 1,419 1,122
Total current assets 44,594 36,975
Other assets and restricted cash [note 7, note 8 and note 9] 183 279
Right-of-use assets [note 13] 64 146
License agreement [note 5 and 6] 1,641 1,864
Goodwill [note 5] 1,034 1,034
Total assets 47,516 40,298
Current liabilities:    
Accounts payable 841 332
Accrued liabilities other 348 584
Accrued clinical liabilities 1,352 453
Accrued compensation 1,940 1,474
Current portion of long-term obligations [note 13] 69 92
Total current liabilities 4,550 2,935
Convertible debt [note 10] 14,920  
Long-term obligations [note 13] 4 77
Total liabilities 19,474 3,012
Commitments and contingencies [note 13]
Stockholders' equity:    
Common stock, $0.001 par value, 150,000,000 shares authorized, 9,453,542 and 6,111,735 issued and outstanding at December 31, 2021 and December 31, 2020, respectively. 79 76
Additional paid-in capital 121,545 97,640
Accumulated deficit (93,586) (60,434)
Accumulated other comprehensive income 4 4
Total stockholders' equity 28,042 37,286
Total liabilities and stockholders' equity 47,516 40,298
Series A Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value